Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib maintenance after autologous stem cell transplant in newly diagnosed multiple myeloma
NL-OMON54581Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Ixazomib maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Nov 2014; status: active, not recruiting.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON54581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54581.